This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed Alunbrig click here.

Why ALUNBRIG  (brigatinib)?

ALUNBRIG: an effective once-daily treatment option in anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (aNSCLC) post crizotinib

ALUNBRIG Packs

Exceeds 1 year median PFSa in ALK+ aNSCLC patients post crizotinib1

  • Systematic ORRb in 56% (97.5% CI 45–67) of patients2
  • Systemic mPFSc of 16.7 months (95% CI 11.6–21.4 months)2
  • mOS of 34.1 months (95% CI 27.7-NR)2

Read more about the systemic efficacy of ALUNBRIG

Effective in the central nervous system (CNS)

  • Intracranial mPFSc,d of 18.4 months (95% CI 12.6–23.9) in patients with any brain metastases at baseline2-5
  • Intracranial mDORc of 16.6 months (95% CI 3.7-NR) in patients with measurable brain metastases at baseline2-5

Read more about the efficacy of ALUNBRIG

A generally manageable tolerability profile

  • The most commone treatment-emergent adverse events are diarrhoea, nausea, cough and increased blood creatine phosphokinase6 which can be managed by dose modification/interruption1
  • Patients should be provided with a Patient Alert Card (PAC). In the first 7 days, they should be closely monitored for adverse reactions, particularly pulmonary adverse reactions, and the dose adjusted or discontinued if necessary1

Read more about the tolerability of ALUNBRIG

Once-daily dosing

  • The convenience of a single tablet, once dailyf, that can be taken with or without food1
  • Treatment should be commenced at the 90mg dose and if tolerated increased to 180mg after 7 days1

Read more about the convenience of ALUNBRIG

a IRC and Investigator assessed.

b Investigator assessed.

c IRC assessed.

d Intracranial PFS does not include systemic (non-cranial) disease progression events.

e Occurred in ≥10% of patients at a frequency of ≥30% at any grade.

f 180 mg once daily with a 7-day-lead-in at 90 mg once daily.


Tools and resources

Takeda Oncology has developed a range of tools and resources for HCPs and patients prescribed ALUNBRIG.

Click here to find out more

Patient support resources